Rainbow Childrens Medicare Limited (RAINBOW) — Financial Results

1 Financial Results 🔴 High Importance Neutral 📄 PDF

Investor Takeaways

Company reported audited standalone and consolidated financial results for Q4FY26 and FY26, recommending a final dividend of ₹3.50 per share (35% on ₹10 face value) subject to shareholder approval at the AGM.

Board re-appointed Dr. Ramesh Kancharla as Chairman and Managing Director for five years (August 11, 2026 – 2031) and Dr. Dinesh Kumar Chirla as Whole Time Director for a similar term.

Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati were re-appointed as Independent Directors for second terms ending in 2031.

Record date for dividend payment and AGM fixed as July 21, 2026; AGM scheduled for July 29, 2026 via VC/OVAM.

Cost Auditors Lavanya & Associates LLP re-appointed for FY 2026-27.

Overall Tone: Neutral based on the numbers only.

Key Financial Highlights

Metric	Value	YoY Change
Revenue	Not available	Not available
Net Profit	Not available	Not available
EBITDA	Not available	Not available
EPS	₹6.76	Not available
OPM	33.75%	Not available

What Changed

Rainbow Children's Medicare released its audited financial results for the quarter and year ended March 31, 2026, alongside recommendations for a final dividend of ₹3.50 per share (35% on ₹10 face value), pending shareholder approval at the upcoming AGM. The company also announced the re-appointment of key managerial personnel, including Dr. Ramesh Kancharla as Chairman and Managing Director for a five-year term (August 11, 2026 – 2031), Dr. Dinesh Kumar Chirla as Whole Time Director for a similar term, and the re-appointment of Independent Directors Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati for second terms ending in 2031. The record date for dividend payment and AGM was fixed as July 21, 2026, with the AGM scheduled for July 29, 2026 via VC/OVAM. Cost Auditors Lavanya & Associates LLP were re-appointed for FY 2026-27. The filing confirms leadership continuity and dividend proposal but does not disclose current-period financial metrics such as revenue, net profit, or EBITDA for the reported period. The company’s market capitalization stands at ₹13,570.33 Cr with a P/E ratio of 52.22, placing it in the healthcare services sector.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Rainbow Childrens Medicare	52.22	Not available	Not available	13,570.33
Sun Pharmaceutical Industries Limited	41.28	15.11%	20.34%	4,50,643.09
Divi's Laboratories Limited	72.41	16.56%	22.09%	1,79,470.03
Torrent Pharmaceuticals Limited	80.06	N/A	N/A	1,49,108.91

Rainbow Children's Medicare has a lower P/E ratio compared to Divi's Laboratories and Torrent Pharmaceuticals but higher than Sun Pharmaceutical Industries Limited. Its market capitalization is significantly smaller than the peers listed.

Risks & Concerns

No specific risks or concerns were identified in the provided filing data.

Quarterly Trend

Quarter	Revenue (₹ Cr)	Net Profit (₹ Cr)	OPM%
Q3FY25	398.08	68.94	33.75

2 Financial Results 🔴 High Importance Neutral 📄 PDF

📢 Key Event
Rainbow Children's Medicare Limited announces FY26 financial results and expansion plans

🔄 What Changed
Revenue grew 12% YoY to ₹1,7031 crores, net profit rose 11% to ₹5442 crores, and EBITDA increased 15% to ₹2815 crores

🔮 What's Next
Planning to open six new hospitals including Prashanthi Hospital in Warangal and Pratiksha Hospital in Guwahati

💡 Investor Takeaway
The company is scaling its pediatric network with strong financial growth, signaling long-term value creation for shareholders through geographic expansion and service deepening.

Rainbow Children's Medicare Limited reported FY26 revenue of ₹1,7031 crores, up 12% YoY, with net profit of [amount context mismatch] crores, up 11%, and EBITDA of [amount context mismatch] crores, up 15%, reflecting strong growth in pediatric and perinatal services across its 24-hospital network. The company highlighted expansion plans including six new hospitals and regional spokes in tier-II cities to deepen market penetration. Governance remains robust with 57 independent directors and 14 women directors on the board, supporting its mission of scalable, high-quality pediatric care.

3 Financial Results 🔴 High Importance Neutral 📄 PDF

Revenue: ₹4,599 CrNet Profit: ₹782 Cr

📢 Key Event
Rainbow Children’s Medicare reported Q4 FY26 revenue of ₹4,599 crores, up 24.3% YoY, with PAT at ₹782 crores (+38.3% YoY).

🔄 What Changed
Revenue grew 24.3% YoY to ₹4,599 crores; PAT grew 38.3% YoY to ₹782 crores; occupancy remained stable at 45.30% despite bed additions; new 60-bed HRBR hospital and IVF centre commissioned in Bengaluru; board proposed 35% dividend.

🔮 What's Next
Occupancy ramp-up across newer facilities; strengthening service mix; improving operating leverage; sustainable patient volume growth; regional hub in Coimbatore to commence operations in H2 FY28; Sector 56 hospital in Gurugram targeted for H2 FY28 commissioning; Pune greenfield hospital excavation started; asset-light 80-bed hospital in Bengaluru signed.

💡 Investor Takeaway
The company completed its expansion phase and is now focused on operational efficiency and profitable growth through occupancy and service optimization.

Rainbow Children’s Medicare reported a 24.3% YoY revenue increase to ₹4,599 crores for Q4 FY26, driven by 18% growth in inpatient discharges and 19% growth in outpatient consultations, with PAT rising 38.3% YoY to ₹782 crores. The company completed its capacity expansion phase, launching a 60-bed HRBR hospital and IVF centre in Bengaluru, while shifting focus to occupancy ramp-up and operational efficiency. Strategic projects in Coimbatore, Gurugram, and Pune advanced with new timelines, and a new asset-light hospital in Bengaluru was secured. The board proposed a 35% dividend, and cash reserves reached ₹5,942 crores to fund future capex.

📊 Stock Analysis — RAINBOW ✨ Ask AI About This

About Rainbow Childrens Medicare Limited (RAINBOW)

Healthcare · Healthcare Services · Listed on NSE

Market Cap: ₹13,570.33 Cr P/E: 52.2

View full RAINBOW stock details →

📡 Get AI alerts when RAINBOW files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track RAINBOW — Free

💡 Ask AI about this filing

"How does this affect RAINBOW margins?" "Compare with last quarter results" "What should investors watch for?"

Ask AI Free →

📊 More RAINBOW filings

See all RAINBOW filings →

🔥 Also filed on 23 May 2026

JKCEMENT JK Cement Limited Financial Results INFY Infosys Limited Corporate Action ADVANIHOTR Advani Hotels & Resorts (India) Limited Corporate Action KAJARIACER Kajaria Ceramics Limited Announcement JKCEMENT JK Cement Limited Corporate Action STUDDS Studds Accessories Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when RAINBOW files new disclosures

Track RAINBOW filings, board meetings, and corporate actions. Free email alerts at 5 PM.